Navigation Links
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Date:1/3/2012

AMSTERDAM, January 4, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B. Orphan designation in the U.S. could provide up to seven years market exclusivity on regulatory approval. Orphan designation for AMT's hemophilia program in the European Union was granted in November 2011.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients, recently published in the New England Journal of Medicine (N Engl J Med 2011; 365:2357-2365), shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"U.S. orphan designation provides additional support for our hemophilia B gene therapy program and supplements the designation in the EU received in November," said Jörn Aldag, CEO of AMT. "The early clinical success seen with the program to date by our partners is very encouraging. We will build on this success in the coming months."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicl
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 Flagship ... analysis services to the pharmaceutical and medical device ... expansion. The fast growing company has consolidated its ... Aurora and Boulder to Westminster, CO, just north of ... Histology Lab, 7575 W. 103rd Ave., Suite 100, Westminster, ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014 is ... of the global isotope ratio mass spectrometer industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, a ... technologies, today announced that it has been selected as ... Industry Association,s 2014 Awards for Excellence competition ... an independent panel of judges from SCORE (Counselors to ... winners will be honored at a gala event to ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... 7 ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading ... cells, announced today that it will be,participating in the ... 10, 2008., The Company,s presentation by Dr. William ... Standard Time (11:50 am, Pacific Standard,Time), and will be ...
... cubes and spheres move aside. Tiny gold stars, smaller ... for new approaches to medical diagnoses or testing for environmental ... wide spectrum of sciences, a new study by Duke University ... stars may shine above all the rest for certain applications. ...
... Upon a Proven Class of Drugs With Greater Tumor ... (Nasdaq: ONXX ) today announced that it has,in-licensed ... Limited based in the United Kingdom. Under the terms ... BGC 945 and all of its,related patents. Onyx will ...
Cached Biology Technology:ThermoGenesis Presentation at Rodman & Renshaw Conference 2Gold nanostar shape of the future 2Gold nanostar shape of the future 3Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 2Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 3
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
(Date:8/26/2014)... of Warwick have provided the first evidence that ... linked to early signs of dementia. , Published ... that the absence of the protein MK2/3 promotes ... nervous system. These changes were shown to have ... including restricted learning and memory formation capabilities. , ...
(Date:8/26/2014)... In recent years, increasing pressure from policymakers, consumers, ... targets that go beyond reducing the pollutants they ... and lakes. Today companies must also assess environmental ... the mining of primary materials to the use ... has given rise to the discipline known as ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2Yale journal explores advances in sustainable manufacturing 2
... 2011 -- Research presented today at the 31st Annual meeting ... Meeting has found that three proteins known as XIAP, BID, ... progesterone treatments in the prevention of preterm labor. They ... The proteins prevent preterm birth by hindering ...
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... the 4th Congress of the International Society for Hemodialysis ... "The Treatment of HCV with Affinity Plasmapheresis." The conference ...
... today at the 31st Annual meeting of the Society for ... three proteins known as XIAP, BID, and Bcl-2 are responsible ... prevention of preterm labor. They may also play an ... proteins prevent preterm birth by hindering apoptosis the normal, ...
Cached Biology News:New research helps explain how progesterone prevents preterm birth 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 3Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 4Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 5New research helps explain how progesterone preventspreterm birth 2
... The new D-LUX Detection Platform combines ... provide the most sensitive, specific, and ... Invitrogens D-LUX Detection Platform offers exceptional ... to TaqMan probes, high signal/background ratio, ...
...
Request Info...
... Blood is aseptically collected via cardiac puncture ... Zealand White, mixed sex). It is then centrifuged ... pooled, sterile filtered and bottled at 4C then ... IF YOU HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU ...
Biology Products: